Therapeutic Potential of Linearol in Combination with Radiotherapy for the Treatment of Glioblastoma In Vitro
Authors:
- Vasiliki ZoiVZVasiliki Zoi
- Theodora PapagrigoriouTPTheodora Papagrigoriou
- Olga S. TsiftsoglouOTOlga S. Tsiftsoglou
- George A. AlexiouGeorge A. Alexiou
- Maria GiannakopoulouMGMaria Giannakopoulou
- Eftychia TzimaETEftychia Tzima
- Pericles TsekerisPTPericles Tsekeris
- Anastasia ZikouAZAnastasia Zikou
- Athanasios P. KyritsisAKAthanasios P. Kyritsis
- Diamanto LazariDLDiamanto Lazari
- Vasiliki GalaniVGVasiliki Galani
Open Access
- 13 February 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3760
Abstract
Glioblastoma is one of the most malignant and lethal forms of primary brain tumors in adults. Linearol, a kaurane diterpene isolated from different medicinal plants, including those of the genus Sideritis, has been found to possess significant anti-oxidant, anti-inflammatory and anti-microbial properties. In this study, we aimed to determine whether linearol could exhibit anti-glioma effects when given alone or in combination with radiotherapy in two human glioma cell lines, U87 and T98. Cell viability was examined with the Trypan Blue Exclusion assay, cell cycle distribution was tested with flow cytometry, and the synergistic effects of the combination treatment were analyzed with CompuSyn software. Linearol significantly suppressed cell proliferation and blocked cell cycle at the S phase. Furthermore, pretreatment of T98 cells with increasing linearol concentrations before exposure to 2 Gy irradiation decreased cell viability to a higher extent than linearol or radiation treatment alone, whereas in the U87 cells, an antagonistic relationship was observed between radiation and linearol. Moreover, linearol inhibited cell migration in both tested cell lines. Our results demonstrate for the first time that linearol is a promising anti-glioma agent and further studies are needed to fully understand the underlying mechanism of this effect.Keywords
This publication has 49 references indexed in Scilit:
- Glioma and glioblastoma - how much do we (not) know?Molecular and Clinical Oncology, 2013
- Role of Glutathione in Cancer Progression and ChemoresistanceOxidative Medicine and Cellular Longevity, 2013
- Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase PromoterCancer Research, 2007
- Kaurane diterpenes protect against apoptosis and inhibition of phagocytosis in activated macrophagesBritish Journal of Pharmacology, 2007
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human GlioblastomasClinical Cancer Research, 2004
- Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomasLaboratory Investigation, 2004
- Kaurane Diterpenes from Isodon japonicus Inhibit Nitric Oxide and Prostaglandin E2 Production and NF-κB Activation in LPS-Stimulated Macrophage RAW264.7 CellsPlanta Medica, 2001
- An ent-kaurane from Sideritis huber-morathiiPhytochemistry, 1996